Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulinastatin for Systemic Inflammatory Response in Cardiac Surgery
NCT04028024Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Aug 2019
- Primary completion
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Open-label trial of ulinastatin in postoperative delirium (POD) and acute kidney injury (AKI), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Postoperative delirium at 7 days and Postoperative renal insufficiency at 7 days. Status: unknown.
02
Drugs
ulinastatin
03
Conditions
postoperative delirium (POD)acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT04028024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04028024.